• Adding Imbruvica to R-CHOP Does Not Improve Outcomes for Newly Diagnosed DLBCL Patients, Phase 3 Trial Shows
  • Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients
  • FDA OKs Adagene’s ADG-106 for Clinical Trial in Solid Tumors, Non-Hodgkin’s Lymphoma
  • How Solitude Can Help Us Survive the Storm
  • Health Canada OKs Gazyva as First-line Therapy for Advanced Follicular Lymphoma
  • Lymphoma Therapies Kymriah, Yescarta Recommended for Approval in Europe
  • Sintilimab Safe, Effective for Relapsed or Refractory Hodgkin’s Lymphoma Patients, Phase 2 Trial Shows
  • Dealing with Sickness in the Midst of Sickness
  • Six-gene Signature Predicts Survival in Mantle Cell Lymphoma Patients, Study Reports
  • FDA Names CPI-613, Potential Treatment for Burkitt’s Lymphoma, an Orphan Drug
  • Umbralisib Linked to Fewer Side Effects in Advanced Lymphoma and Leukemia Patients, Data Show
  • Don’t Let Lymphoma Stop You From Living